Clinical trial · Interventional
Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer
Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial)
NCT00553124CI-TRIAL-00013382unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying different factors that effect patients with newly diagnosed bladder cancer may help doctors learn more about the disease, improve the ability to plan cancer treatment, and help patients live more comfortably. PURPOSE: This clinical trial is studying different factors affecting patients with newly diagnosed bladder cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (16)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy | Procedure | — | UNRESOLVED |
| chemoprevention | Procedure | — | UNRESOLVED |
| cryopreservation | Procedure | — | UNRESOLVED |
| cytology specimen collection procedure | Procedure | — | UNRESOLVED |
| diagnostic procedure | Procedure | — | UNRESOLVED |
| gene expression analysis | Procedure | — | UNRESOLVED |
| immunohistochemistry staining method | Procedure | — | UNRESOLVED |
| laboratory biomarker analysis | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Recurrence-free interval
- measure
- Progression-free interval
Secondary outcomes (5)
- measure
- Overall survival time
- measure
- Incidence of transitional cell carcinoma outside the bladder
- measure
- Incidence of all other malignancies clinically diagnosed
- measure
- Incidence of cardiovascular events
- measure
- Quality of life as measured by EORTC QLQ-C30, QLQ-BLS24 and QLQ-BLM30 questionnaires
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma meeting 1 of the following criteria: * Non-muscle-invasive tumor * Muscle-invasive tumor * Solitary G1 pTa tumor * No previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within the 10 years prior to current diagnosis PATIENT CHARACTERISTICS: * Fit for cystoscopy and surgical biopsy/resection * No HIV infection * No condition that, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the study objectives PRIOR CONCURRENT THERAPY: * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.